Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nalmefene
- Development stage
- Approved
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral, Intranasal, Intravenous, Intramuscular, Subcutaneous
01
Overview
Nalmefene is an opioid receptor antagonist used primarily for the treatment of opioid overdose and alcohol dependence. It acts as an antagonist at mu-opioid and delta-opioid receptors and as a partial agonist at the kappa-opioid receptor. By blocking these receptors in the brain's reward system, nalmefene reduces the rewarding effects of opioids and alcohol. This mechanism helps reverse life-threatening symptoms of opioid overdose (such as respiratory depression) and decreases alcohol consumption in individuals with alcohol dependence. Nalmefene has a longer duration of action than naloxone and does not induce tolerance or physical dependence[1][2][5][8]. It can be administered orally, intranasally, or by injection.
- Brand names
- Revex
- Other names
- nalmefene
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on nalmefene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nalmefene.